J&J responds to Reminyl “not-approvable” letter
Executive Summary
Johnson & Johnson has responded to FDA's "not-approvable" letter for an extended-release formulation of its Alzheimer's agent Reminyl (galantamine), company says at Bear Stearns health care conference. J&J says FDA's concerns relate to "some statistical issues around the interpretation of our studies." Company received the "not-approvable" letter in December (1"The Pink Sheet" April 19, 2004, p. 12)...
You may also be interested in...
J&J Antipsychotic Paliperidone ER Moves Into Phase III
Johnson & Johnson has moved a potential successor compound to the antipsychotic Risperdal into Phase III clinical studies
Roche/Genentech Keeps Commitment To External Cancer Innovation
Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.
US FDA Eases Changes For Certain Sterile Injectable Container Closure Materials
To mitigate pandemic disruption of component supply chains, the US FDA said it will downgrade some post-approval change categories for sterile drug container closure systems. The downgrade will cover drugs in shortage and those used to treat COVID-19.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: